Beta Drugs IPO Basis of Allotment

BETA DRUGS LIMITED

Our Company was incorporated as 'Beta Drugs Private limited' at Himachal Pradesh as a private limited company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated September 21, 2005 bearing Corporate Identification Number U24230HP2005PTC28969 issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Subsequently, our Company was converted in to public limited company pursuant to Shareholders Resolution passed at the Extra-Ordinary General Meeting of our Company held on July 24, 2017 and the name of our Company was changed to 'Beta Drugs Limited' pursuant to issuance of fresh Certificate of Incorporation consequent upon conversion of Company from Private to Public Limited dated August 11,2017 issued by the Registrar of Companies, Himachal Pradesh. The Corporate Identification Number of our Company is U24230HP2005PLC028969. For further details of Business, Incorporation, Change of Name and Registered Office of our company, please refer to chapter titled 'General Information' and 'Our History and Certain Other Corporate Matters' beginning on page 64 and page 169 of this Prospectus

Registered Office: Village Nandpur Baddi Himachal Pradesh-17410 India Tel No. 01795-236196 Fax No.: Not available; Email: info@betadrugslimited.com;
Website: www.betadrugslimited.com Corporate Identification Number: U24230HP2005PLC028969; Contact Person: Rajni Brar, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY: : VIJAY KUMAR BATRA

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 22,96,000 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH ('EQUITY SHARES') OF BETA DRUGS LIMITED (THE 'COMPANY' OR THE 'ISSUER') FOR CASH AT A PRICE OF RS. 85 PER EQUITY SHARE, INCLUDING A SHARE PREMIUM OF RS.75 PER EQUITY SHARE (THE 'ISSUE PRICE'), AGGREGATING RS. 1951.60 LAKHS ('THE ISSUE'), OF WHICH 1,29,600 EQUITY SHARES OF FACE VALUE RS. 10 EACH FOR CASH AT A PRICE OF RS. 85 PER EQUITY SHARE, AGGREGATING RS. 110.16 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE 'MARKET MAKER RESERVATION PORTION'). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 21,66,400 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH FOR CASH AT A PRICE OF RS.85 PER EQUITY SHARE, AGGREGATING RS. 1841.44 LAKHS IS HEREINAFTER REFERED TO AS THE 'NET ISSUE'. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.54% AND 25.05% RESPECTIVELY OFTHE FULLY DILUTED POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

In terms of Prospectus dated September 19, 2017 and as per Regulation 43(4) of SEBI (ICDR) Regulations, 2009 wherein

(a) minimum of 50% of the Net Offer to Public shall initially be made available to Retail Individual Investors.
(b) the balance net offer of shares to the public shall be made available for allotment to
(i) individual applicants other than retail investors and
(ii) other investors including corporate bodies / institutions irrespective of no. of shares applied for.
(c) the unsubscribed portion of the net offer to any one of the categories specified in (a) or (b) shall/may be made available for allocation in any other category, if so required.

Explanation: for the purpose of Regulation 43(4) of SEBI (ICDR) Regulations, 2009, if the retail individual investor is entitled to more than fifty percent, on proportionate basis, the retail individual investors shall be allocated that higher percentage. All Investors have participated in this offer through ASBA process. For details in this regards, specific attention is invited to chapter 'Issue Procedure' on page 292 of the Prospectus.

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ('NSE EMERGE'). In terms of the Chapter XB of the SEBI (ICDR) Regulations, 2009 as amended from time to time, our Company has received an In principle approval letter dated September 18, 2017from National Stock Exchange of India Limited for using its name in the offer Document for listing of our Shares on EMERGE Platform of National Stock Exchange of India Limited. The designated stock exchange is EMERGE Platform of the National Stock Exchange of India Limited ('NSE EMERGE')

SUBSCRIPTION DETAILS

The Issue has received 5,556 applications for 4,12,16,000 Equity shares (Before Technical Rejection, Bids not Banked and after Invalid Duplicate Bids) (including Market Maker Application of 1,29,600 Equity Shares) resulting 17.95 times subscription. After considering, Technical Rejection cases, the issue was subscribed 17.75 times (including the Market Maker Portion). The details of application received (Before Technical Rejection and after Bids not banked

The details of applications rejected by the Registrar on technical grounds are detailed below:

Detail of the Applications Received (After Technical Rejection and bids not banked):

ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange - National Stock Exchange of India Limited on October 10, 2017.

A. Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the issue price of Rs. 85/- per Equity Share, was finalized in consultation with National Stock Exchange of India Limited. The category was subscribed by 1.00 times. The total number of shares allotted in this category is 1,29,600 Equity Shares infull out of reserved portion 1,29,600 Equity Shares.

B. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotmentto the Retail Individual Investors, at the issue price of Rs. 85/- per Equity Share, was finalized in consultation with National Stock Exchange of India Limited. The category was subscribed by 7.64 times. Total number of shares allotted in this category is 10,83,200 Equity Shares. The category wise basis of allotment is as under:

C. Allocation to Other than Retail Individual Investor (After Technical Rejection): The Basis of Allotmentto other than Retail Individual Investors, at the issue price of Rs 85/-per Equity Share, was finalized in consultation with National Stock Exchange of India Limited. The category was subscribed by 29.86 times. Total number of shares allotted in this category is 10,83,200 Equity Shares. The category wise basis of allotment is as under:

The Board of Directors of the Company at its meeting held on October 10, 2017 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange viz. National Stock Exchange of India Limited and authorized corporate action for allotment of shares in dematerialized form to various successful applicants.
The CAN and allotment advice and/or notices shall be dispatched to the address of the Applicants as registered with the depositories / as filled in the application form on or before October 10, 2017. Further, the instructions to SCSBs shall be issued on October 10, 2017 for unblocking of funds. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. In case the same is not received within prescribed time, Investors may contact the registrar to the Issue at the address given below. The Company is taking steps to get the Equity Shares admitted for trading on the EMERGE Platform of National Stock Exchange of India Limited within six working days from the date of the closure of the Issue. The trading is proposed to commence on or before October 12,2017 subject to receipt of listing and trading approval from National Stock Exchange of India Limited.

INVESTORS PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue at www.linkintime.co.in All future correspondence in this regard may kindly be addressed to the Registrar quoting full name of the First/ Sole applicant, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

_{LINK INTIME INDIA PRIVATE LIMITED}
C-101,1st Floor, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400083 India.
Tel: 022-49186200; Fax: 022-49186195 Email: betadrugs.ipo@linkintime.co.in 
Website: www.linkintime.co.in Investor Grievance Id: betadrugs.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan; SEBI Registration No.: INR000004058